https://allsci.com/news/clinical-trials/rig-101-phase-ii-trial-leyden-labs-advances-into/ AllScien 2026-09-09T12:55:18.743940Z Leyden Labs advances RIG-101 after Phase I shows safety and on-target immune activation https://allsci.com/news/clinical-trials/pra-216-phase-i-results-sustains-dual-pathway/ AllScien 2026-09-09T12:46:54.623834Z Prana reports prolonged Type 2 biomarker suppression with IL-4Rα/TSLP bispecific https://allsci.com/news/clinical-trials/pmb-ct01-car-t-therapy-achieves-complete/ AllScien 2026-09-09T12:42:16.868751Z Lancet data show durable responses with PeproMene's BAFF-R CAR T after CD19 CAR T failure https://allsci.com/news/clinical-trials/deucrictibant-xr-hae-pharvariss-cuts-attack-rate/ AllScien 2026-09-09T12:37:07.178370Z Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy https://allsci.com/news/venture-financing/tectora-therapeutics-series-a-funding-schrodinger/ AllScien 2026-09-09T12:10:07.413332Z Schrödinger spins out Tectora with USD 55m Series A for immunology programs https://allsci.com/news/licensing-and-partnerships/assembly-bio-gilead-hsv-profit-share-converts/ AllScien 2026-09-09T11:25:27.482739Z Assembly Bio converts HSV program from royalty deal to 40% US profit-share with Gilead https://allsci.com/news/clinical-trials/alpha-1-antitrypsin-gene-therapy-beams-base/ AllScien 2026-09-09T09:34:04.038634Z Beam reports durable BEAM-302 AAT restoration, advances pivotal cohort https://allsci.com/news/ipo-public-listing/korsana-ipo-alzheimers-goes-public-with-usd-380m/ AllScien 2026-09-09T09:20:16.811904Z Korsana goes public with USD 380m raise and Alzheimer's antibody poised for Phase I https://allsci.com/news/clinical-trials/evo756-phase-iib-trial-failure-fails-second-in/ AllScien 2026-09-09T08:41:23.493838Z Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss https://allsci.com/news/research/rentosertib-biological-age-reversal-insilicos-ipf/ AllScien 2026-09-08T17:46:38.174222Z Insilico's IPF drug rentosertib shows biological age reversal in exploratory proteomic analysis https://allsci.com/news/clinical-trials/semaglutide-children-obesity-clears-treatment/ AllScien 2026-09-08T17:42:19.901358Z Semaglutide clears obesity treatment threshold in children aged 6 to under 12 https://allsci.com/news/corporate-strategy/sernova-seraxis-merger-and-to-combine-cell-pouch/ AllScien 2026-09-08T17:36:57.445493Z Sernova, Seraxis merge to build integrated stem cell islet replacement platform for T1D https://allsci.com/news/venture-financing/trna-cancer-therapeutics-funding-cloverleaf-bio/ AllScien 2026-09-08T17:33:27.513576Z Cloverleaf Bio lands USD 33m seed with Lilly, AbbVie, and Boehringer backing https://allsci.com/news/clinical-trials/an01-copd-trial-dual-pde34-inhibitor-meets/ AllScien 2026-09-08T17:28:03.975331Z AirNexis’s AN01 improves lung function on top of bronchodilators in COPD https://allsci.com/news/clinical-trials/skb378-phase-iii-asthma-skb378win378-advances-to/ AllScien 2026-09-08T17:14:23.611179Z Windward’s TSLP mAb shows six-month asthma activity after single dose https://allsci.com/news/regulatory/crispr-therapy-hereditary-angioedema-fda-grants/ AllScien 2026-09-08T16:53:04.566436Z Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date https://allsci.com/news/clinical-trials/arlocabtagene-autoleucel-approval-bristol-myers/ AllScien 2026-09-08T16:45:53.392817Z BMS’s GPRC5D CAR-T clears registrational trial in quadruple-exposed multiple myeloma https://allsci.com/news/clinical-trials/inbrx-106-head-and-neck-cancer-inhibrxs-nearly/ AllScien 2026-09-08T16:33:23.949933Z Inhibrx's OX40 agonist nearly doubles response rate versus Keytruda alone in head and neck cancer https://allsci.com/news/research/ai-protein-rna-delivery-ai-designed-vehicles-from/ AllScien 2026-09-08T16:22:03.222760Z German researchers show AI-designed protein vehicles outperform lipid nanoparticles in RNA delivery https://allsci.com/news/clinical-trials/ziltivekimab-phase-iii-trials-stopped-novo/ AllScien 2026-09-08T16:12:06.916844Z Novo Nordisk scraps two Phase III ziltivekimab trials after ZEUS failure https://allsci.com/news/pipe-financing/colorectal-cancer-immunotherapy-funding/ AllScien 2026-09-08T15:24:09.654593Z PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC https://allsci.com/news/clinical-trials/tarlatamab-durvalumab-es-sclc-plus-beats/ AllScien 2026-09-08T15:04:18.241149Z Amgen’s tarlatamab delivers Phase III OS win in first-line ES-SCLC maintenance https://allsci.com/news/venture-financing/moonwalk-biosciences-series-b-funding-raises-usd/ AllScien 2026-09-08T14:52:58.710196Z Moonwalk Bio raises USD 70m Series B for adipose-targeted obesity therapies https://allsci.com/news/clinical-trials/tozorakimab-copd-exacerbations-cuts-across-all/ AllScien 2026-09-08T14:46:50.651150Z AZ’s tozorakimab shows Phase III benefit across eosinophil levels in COPD https://allsci.com/news/approvals/etcamah-breast-cancer-fda-approval-approves-to/ AllScien 2026-09-08T14:33:40.203800Z FDA approves AZ’s Etcamah for pre-progression switch in HR+ breast cancer https://allsci.com/news/clinical-trials/pelacarsen-cardiovascular-trial-failure/ AllScien 2026-09-08T14:13:37.996035Z Novartis’s pelacarsen misses Phase III endpoint despite deep Lp(a) lowering https://allsci.com/news/clinical-trials/del-desiran-phase-iii-myotonic-dystrophy/ AllScien 2026-09-08T13:52:10.140652Z Novartis’s Avidity-acquired del-desiran falls short in Phase III DM1 trial https://allsci.com/news/venture-financing/car-t-therapy-pediatric-brain-cancer-brainchild/ AllScien 2026-09-08T13:32:45.098991Z BrainChild Bio raises USD 116m to advance CAR T therapy for pediatric brain cancer